Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INSPIRE: Rigosertib in MDS
NCT02562443Phase 3Terminated
- Sponsor
- Traws Pharma, Inc.
- Start
- Dec 2015
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 22
01
Overview
Phase 3, randomised, open-label trial of rigosertib in myelodysplastic syndrome (MDS) (2 arms), sponsored by Traws Pharma, Inc. Primary endpoint: Overall Survival at 30 months. Started Dec 2015; status: terminated.
02
Drugs
rigosertib
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02562443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02562443.